Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+1.03%
$117.03
100% positive prob.
5-Day Prediction
+2.37%
$118.59
100% positive prob.
20-Day Prediction
+0.84%
$116.82
95% positive prob.
SEC 8-K filings with transcript text
Feb 3, 2026 · 100% conf.
1D
+1.03%
$117.03
Act: +2.13%
5D
+2.37%
$118.59
Act: +1.13%
20D
+0.84%
$116.82
Act: +3.81%
false 0000310158
0000310158
2026-02-03 2026-02-03
0000310158
us-gaap:CommonStockMember
2026-02-03 2026-02-03
0000310158
mrk:Sec1.875NotesDue2026Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.250NotesDue2032Member
2026-02-03 2026-02-03
0000310158
mrk:Sec2.500NotesDue2034Member
2026-02-03 2026-02-03
0000310158
mrk:Sec1.375NotesDue2036Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.500NotesDue2037Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.700NotesDue2044Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.750NotesDue2054Member
2026-02-03 2026-02-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 3, 2026 (February 3, 2026)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (908) 740-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 3, 2026, regarding earnings for the fourth quarter and year end of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued February 3, 2026, regarding earnings for the fourth quarter and year end of 2025
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: February 3, 2026 By:
/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Oct 30, 2025
false 0000310158
0000310158
2025-10-30 2025-10-30
0000310158
us-gaap:CommonStockMember
2025-10-30 2025-10-30
0000310158
mrk:Sec1.875NotesDue2026Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.250NotesDue2032Member
2025-10-30 2025-10-30
0000310158
mrk:Sec2.500NotesDue2034Member
2025-10-30 2025-10-30
0000310158
mrk:Sec1.375NotesDue2036Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.500NotesDue2037Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.700NotesDue2044Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.750NotesDue2054Member
2025-10-30 2025-10-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 30, 2025 (October 30, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (908) 740-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on October 30, 2025, regarding earnings for the third quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued October 30, 2025, regarding earnings for the third quarter of 2025
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: October 30, 2025 By:
/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Jul 29, 2025
false 0000310158
0000310158
2025-07-25 2025-07-25
0000310158
us-gaap:CommonStockMember
2025-07-25 2025-07-25
0000310158
mrk:Sec1.875NotesDue2026Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.250NotesDue2032Member
2025-07-25 2025-07-25
0000310158
mrk:Sec2.500NotesDue2034Member
2025-07-25 2025-07-25
0000310158
mrk:Sec1.375NotesDue2036Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.500NotesDue2037Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.700NotesDue2044Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.750NotesDue2054Member
2025-07-25 2025-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 29, 2025 (July 25, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (732) 594-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on July 29, 2025, regarding earnings for the second quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 2.05. Costs Associated with Exit or Disposal Activities.
On July 25, 2025, the Company approved a new restructuring program (2025 Restructuring Program) designed to position the Company for its next chapter of growth and to successfully advance its pipeline and launch new products across multiple therapeutic areas. As part of this program, the Company expects to eliminate certain positions in sales and administrative organizations, as well as research and development. The Company will, however, continue to hire employees into new roles across all strategic growth areas of the business. In addition, the Company will reduce its global real estate footprint and continue to optimize its manufacturing network, aligning the geography of its global manufacturing footprint to its customers and reflecting changes in the Company’s business.
Most actions contemplated under the 2025 Restructuring Program are expected to be largely completed by the end of 2027, with the exception of certain manufacturing actions, which are expected to be substantially completed by the end of 2029. The cumulative pretax costs to
This page provides Merck & Company Inc. (new) (MRK) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on MRK's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.